Trial · NCT00328094
Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery
NCT00328094, Not applicable, Terminated, Beth Israel Deaconess Medical Center; results first posted 2013-04-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery. Trials, record NCT00328094. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00328094
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery
- NCT number
- NCT00328094
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 242 participants, actual
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Conditions
- Peripheral Vascular Disease, Abdominal Aortic Aneurysm
- Interventions
- continuous intravenous insulin infusion
- First posted
- 2006-05-19
- Last updated
- 2013-04-17
- Results first posted
- 2013-04-09
- Limitations and caveats
A trial to adequately address mortality would require 5000 to 6000 patients. The alpha levels for significance were not adjusted for the interim analyses because of the unplanned issues with subject recruitement as surgery became percutaneous.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite (Myocardial Infarction and CHF) | hospital length of stay | |
| Secondary | Incidence of Wound Infections | postoperative |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Incidence of Wound Infections | postoperative | participants | NUMBER | |
| PRIMARY | Composite (Myocardial Infarction and CHF) | hospital length of stay | Number of patients | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Wound Infections | Continuous Insulin Infusion | 35 | participants | ||
| Incidence of Wound Infections | Intermittent Insulin Bolus | 29 | participants | ||
| Composite (Myocardial Infarction and CHF) | Continuous Insulin Infusion | 4 | Number of patients | ||
| Composite (Myocardial Infarction and CHF) | Intermittent Insulin Bolus | 15 | Number of patients |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Continuous Insulin Infusion | 117 | |
| Overall Study | STARTED | Intermittent Insulin Bolus | 125 | |
| Overall Study | COMPLETED | Continuous Insulin Infusion | 114 | |
| Overall Study | COMPLETED | Intermittent Insulin Bolus | 122 | |
| Overall Study | NOT COMPLETED | Continuous Insulin Infusion | 3 | |
| Overall Study | NOT COMPLETED | Intermittent Insulin Bolus | 3 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Creatinine > 25% increase | Renal and urinary disorders | Continuous Insulin Infusion | 23 | 114 | 23 |
| other | Creatinine > 25% increase | Renal and urinary disorders | Intermittent Insulin Bolus | 22 | 122 | 22 |
| serious | HYPOGLYCEMIA | Metabolism and nutrition disorders | Continuous Insulin Infusion | 10 | 114 | 10 |
| serious | HYPOGLYCEMIA | Metabolism and nutrition disorders | Intermittent Insulin Bolus | 5 | 122 | 5 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Continuous Insulin Infusion | ||
| Total, all-cause mortality | Intermittent Insulin Bolus | ||
| Total, other adverse events | Continuous Insulin Infusion | 23 | 114 |
| Total, other adverse events | Intermittent Insulin Bolus | 22 | 122 |
| Total, serious adverse events | Continuous Insulin Infusion | 10 | 114 |
| Total, serious adverse events | Intermittent Insulin Bolus | 5 | 122 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Continuous Insulin Infusion vs Intermittent Insulin Bolus: Incidence of Wound Infections | Trial comparisons |
| Continuous Insulin Infusion vs Intermittent Insulin Bolus: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00328094
GET https://conductscience.org/api/trials/v1/NCT00328094/registered